PFE faces a decline in COVID revenues, LOE pressure and IRA impacts but rising EPS estimates offer a glimmer of resilience.

BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 10 biotech stocks screaming a buy. On June 17, Wolfe Research initiated ...

PFE's new drug launches and Seagen acquisition are driving revenue gains despite COVID declines and market headwinds.

The advent of ATTR-specific drugs, though pricey, is enabling better survival in these overlapping diseases, researchers say.

Vyndaqel Global Market Report 2025 The Business Research Company's Vyndaqel Global Market Report 2025 – Market Size, Trends, And Global Fo. Tuesday, 02 January 2024 12:17 GMT.

Attruby carries a list price of $18,759.12 for a 28-day supply, while Vyndaqel has a list price of about $268,000 annually for a once-daily dose of 80 milligrams.

Attruby carries a list price of $18,759.12 for a 28-day supply, while Vyndaqel has a list price of about $268,000 annually for a once-daily dose of 80 milligrams.

Attruby carries a list price of $18,759.12 for a 28-day supply, while Vyndaqel has a list price of about $268,000 annually for a once-daily dose of 80 milligrams.

The broad label that will be attached to Attruby, which will state the oral drug reduces risk of both death and hospitalisation, is a major boost for BridgeBio, as it is the same as Vyndaqel's ...

Pfizer posted Q4 revenue of $17.76 billion, up 22% YoY, with strong sales from Paxlovid, Vyndaqel, and Eliquis. The company reaffirmed its 2025 revenue outlook.

Vyndaqel sales were up 66% y-o-y to $3.9 billion for the nine-month period ending Sep 2024, while Eliquis sales were up 8% to $5.5 billion.